Publication details
Casodex 150 při ovlivnění progrese karcinomu prostaty u pacientů s rizikovými faktory léčených s kurativním záměrem
| Title in English | Casodex 150 - effect on prostate cancer progression in patients with risk factors treated with curative intention |
|---|---|
| Authors | |
| Year of publication | 2005 |
| Type | Peer-reviewed scientific article |
| Magazine / Source | Urológia |
| MU Faculty or unit | |
| Citation | |
| Field | Other medical specializations |
| Keywords | Prostate cancer - adjuvant hormonal therapy - bicalutamid |
| Description | risk of biochemical recurrence of prostate cancer in patients treated with curative intention is up to 30% during 10 years even if the therapy indication of this group was very carefully indicated. Risk factors (PSA > 10 ng/ml, Gleason score > 7, stage of disease pT2b and more) increase risk of recurrence. Bicalutamid 150 ( Casodex ) is the only one drug, that can decrease this risk - based on scientific research results. |